EGFR and cancer: PSA values at diagnosis (P = 0.009), Gleason score (P<0.001), clinical tumor stage (P = 0.011), distant metastasis (P = 0.006), Ki-67 LI (P = 0.002), EGFR amplification (P = 0.023), and HER2 amplification (P = 0.001) were also significantly related to cancer-related survival in univariate analysis.